Why the study?
Does AT1R blockade with candesartan suppress tumor invasion, angiogenesis, and peritoneal dissemination in ovarian carcinoma models?
Population
Human ovarian tumor tissues, AT1R-positive SKOV-3 ovarian cancer cells, and SKOV-3-transplanted athymic mice
Comparison
AT1R blocker (candesartan) vs Untreated control
Design
Preclinical
Authors
Loading...
Supports AT1R blockade as a potential target in ovarian carcinoma; hypothesis-generating and requires clinical validation.
Does AT1R blockade with candesartan suppress tumor invasion, angiogenesis, and peritoneal dissemination in ovarian carcinoma models?
AT1R blockade with candesartan suppresses tumor progression and angiogenesis in preclinical models of ovarian carcinoma, suggesting a potential novel therapeutic strategy.
Suganuma et al. (2005) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: